The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Cambrex Corp

NYSE: CBM
Last

(U.S.) $36.50

Today's change+0.15 +0.41%
Updated February 11 4:02 PM EST. Delayed by at least 15 minutes.
 

Cambrex Corp

NYSE: CBM
Last

(U.S.) $36.50

Today's change+0.15 +0.41%
Updated February 11 4:02 PM EST. Delayed by at least 15 minutes.

Cambrex Corp crosses above 20-day moving average

Cambrex Corp closed up Thursday by (U.S.)$0.15 or 0.41% to (U.S.)$36.50 and crossing above its 20-day moving average. Over the last five days, shares have gained 7.07%, but are down 22.49% for the last year to date. Shares have outperformed the S&P 500 by 26.94% during the last year.

Key company metrics

  • Open(U.S.) $34.97
  • Previous close(U.S.) $36.35
  • High(U.S.) $36.95
  • Low(U.S.) $34.63
  • Bid / Ask(U.S.) $36.50 / (U.S.) $36.51
  • YTD % change-22.49%
  • Volume925,551
  • Average volume (10-day)835,184
  • Average volume (1-month)645,282
  • Average volume (3-month)502,692
  • 52-week range(U.S.) $29.50 to (U.S.) $55.60
  • Beta1.26
  • Trailing P/E20.80×
  • P/E 1 year forward15.02×
  • Forward PEG1.00×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $1.76
Updated February 11 4:02 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+13.19%

Based on its net profit margin of 13.19%, Cambrex Corp is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.81%Sector:HealthcareIndustry:Pharmaceuticals - Diversified
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2015Q2/2015Q1/2015Q4/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201509/30/2015Jun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014
Revenue9310778129
Total other revenue--------
Total revenue9310778129
Gross profit36462945
Total cost of revenue57614884
Total operating expense757765107
Selling / general / administrative14141414
Research & development4333
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)------6
Other operating expenses, total--------
Operating income18291323
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax17291222
Income after tax1219828
Income tax, total594-6
Net income1220828
Total adjustments to net income--------
Net income before extra. items1219828
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items1219828
Inc. avail. to common incl. extra. items1220828
Diluted net income1220828
Dilution adjustment--------
Diluted weighted average shares33323232
Diluted EPS excluding extraordinary itemsvalue per share0.360.600.260.88
Dividends per sharevalue per share0.000.000.00--
Diluted normalized EPSvalue per share0.360.600.261.00